NasdaqGS - Delayed Quote
USD
Spero Therapeutics, Inc. (SPRO)
2.7800
+0.0600
(+2.21%)
At close: April 9 at 4:00:00 PM EDT
Trade SPRO on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for SPRO
- Previous Close
2.7200 - Open
2.7200 - Bid 2.7500 x 100
- Ask 2.8300 x 100
- Day's Range
2.6700 - 2.8000 - 52 Week Range
0.5220 - 3.2200 - Volume
446,503 - Avg. Volume
330,206 - Market Cap (intraday)
160.938M - Beta (5Y Monthly) 1.45
- PE Ratio (TTM)
18.53 - EPS (TTM)
0.1500 - Earnings Date (est.) May 13, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.00
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
sperotherapeutics.comRecent News: SPRO
View More
Performance Overview: SPRO
Trailing total returns as of 4/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
SPRO
19.31%
S&P 500 (^GSPC)
0.30%
1-Year Return
SPRO
371.19%
S&P 500 (^GSPC)
25.06%
3-Year Return
SPRO
84.11%
S&P 500 (^GSPC)
66.25%
5-Year Return
SPRO
78.75%
S&P 500 (^GSPC)
65.29%
Earnings Trends: SPRO
View MoreAnalyst Insights: SPRO
View MoreStatistics: SPRO
View MoreValuation Measures
As of 4/9/2026
-
Market Cap
160.94M
-
Enterprise Value
123.57M
-
Trailing P/E
18.53
-
Forward P/E
--
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
2.75
-
Price/Book (mrq)
2.73
-
Enterprise Value/Revenue
2.07
-
Enterprise Value/EBITDA
17.26
Financial Highlights
Profitability and Income Statement
-
Profit Margin
12.83%
-
Return on Assets (ttm)
4.99%
-
Return on Equity (ttm)
16.30%
-
Revenue (ttm)
66.8M
-
Net Income Avi to Common (ttm)
8.57M
-
Diluted EPS (ttm)
0.1500
Balance Sheet and Cash Flow
-
Total Cash (mrq)
40.27M
-
Total Debt/Equity (mrq)
4.91%
-
Levered Free Cash Flow (ttm)
-4.25M
Compare To: SPRO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: SPRO
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
